⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Allotera Therapeutics (formerly Wugen, Inc.) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Allotera Therapeutics (formerly Wugen) is a clinical-stage biotechnology company focused on developing next-generation, allogeneic CAR-T cell therapies for cancer. The company utilizes a proprietary gene-editing platform designed to overcome the limitations of first-generation cell therapies, enabling scalable, off-the-shelf treatments with favorable cost-of-goods margins.
Originally founded as Wugen in 2018 in St. Louis, the company has expanded its focus to include memory natural killer (NK) and CAR-T cell therapies. Following a significant rebranding in 2026, the company continues to advance its lead candidate, Soficabtagene Geleucel (Sofi-cel), which is currently being evaluated in a global pivotal clinical trial for relapsed or refractory T-cell malignancies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$251M
Investors:Fidelity Management & Research, Abingworth, Tybourne Capital Management, RiverVest Venture Partners, Lightchain Capital, BioGenerator, Intermediate Capital Group, Aisling Capital Management
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (Pivotal)
Modalities:Cell therapy, CAR-T, NK cell therapy
Active Trials:9
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Washington University in St. Louis (Technology licensing), Blood Cancer United (Therapy Acceleration Program)
COMPETITION
Position:Emerging
Competitors:Fate Therapeutics, Allogene Therapeutics, CRISPR Therapeutics, Nkarta, Artiva Biotherapeutics
LEADERSHIP
Key Executives:
Kumar Srinivasan - CEO
Scientific Founders:Miro Brajenovic, Matthew Cooper
Board Members:Natalie Mount (Chair)
LINKS
Website:wugen.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Allotera Therapeutics (formerly Wugen, Inc.). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.